Incyte (INCY)

86.70 +0.91 (1.06%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/14/20 *Est.)
- Conference (12/4/2019)

Latest Headlines

Form 4 INCYTE CORP For: Nov 13 Filed by: Pasquale Maria E November 14, 2019 5:33 PM - SEC Filing Incyte to Present at Upcoming Investor Conference November 14, 2019 8:00 AM - BizWire Form 4 INCYTE CORP For: Nov 06 Filed by: DIXON WENDY L November 8, 2019 5:25 PM - SEC Filing Form CT ORDER INCYTE CORP November 7, 2019 4:07 PM - SEC Filing Form CT ORDER INCYTE CORP November 7, 2019 1:25 PM - SEC Filing Form CT ORDER INCYTE CORP November 7, 2019 1:17 PM - SEC Filing Form CT ORDER INCYTE CORP November 7, 2019 1:06 PM - SEC Filing Form CT ORDER INCYTE CORP November 7, 2019 12:59 PM - SEC Filing Form 4 INCYTE CORP For: Nov 01 Filed by: Wenqing Yao November 5, 2019 5:24 PM - SEC Filing Form 4 INCYTE CORP For: Nov 01 Filed by: Trower Paul November 5, 2019 4:33 PM - SEC Filing Form 4 INCYTE CORP For: Oct 29 Filed by: Wenqing Yao October 31, 2019 4:10 PM - SEC Filing Form 4 INCYTE CORP For: Oct 29 Filed by: Trower Paul October 31, 2019 4:08 PM - SEC Filing Form 4 INCYTE CORP For: Oct 30 Filed by: Stein Steven H October 31, 2019 4:04 PM - SEC Filing Form 4 INCYTE CORP For: Oct 29 Filed by: Iyengar Vijay K October 31, 2019 4:01 PM - SEC Filing Incyte (INCY) PT Raised to $89 at Morgan Stanley October 30, 2019 8:05 AM - StreetInsider Incyte (INCY) PT Raised to $98 at Mizuho Securities October 30, 2019 8:03 AM - StreetInsider Incyte (INCY) PT Raised to $85 at RBC Capital October 30, 2019 6:30 AM - StreetInsider Form 10-Q INCYTE CORP For: Sep 30 October 30, 2019 6:11 AM - SEC Filing Incyte (INCY) Tops Q3 EPS by 17c, Revenues Beat; Raises FY19 Jakafi Revenue Outlook October 29, 2019 7:12 AM - StreetInsider Form 8-K INCYTE CORP For: Oct 29 October 29, 2019 7:10 AM - SEC Filing Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 29, 2019 7:00 AM - BizWire Form 4 INCYTE CORP For: Oct 22 Filed by: SWAIN PAULA J October 24, 2019 6:53 PM - SEC Filing Incyte to Present at Upcoming Investor Conference October 22, 2019 8:00 AM - BizWire Incyte (INCY) PT Lowered to $82 at RBC Capital October 17, 2019 6:38 AM - StreetInsider Incyte (INCY) Reports REACH2 Pivotal Trial of Ruxolitinib (Jakafi) Meets Primary Endpoint October 16, 2019 7:01 AM - StreetInsider Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease October 16, 2019 7:00 AM - BizWire Mizuho Securities Reiterates Buy Rating on Incyte (INCY) October 14, 2019 6:49 AM - StreetInsider Incyte (INCY) Reports Positive 52-Wk Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo October 14, 2019 6:14 AM - StreetInsider Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo October 12, 2019 2:32 AM - BizWire Form 4 INCYTE CORP For: Oct 10 Filed by: Pasquale Maria E October 11, 2019 4:40 PM - SEC Filing Incyte to Report Third Quarter Financial Results October 10, 2019 8:00 AM - BizWire Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress October 8, 2019 6:45 AM - PR NewsWire Form 4 INCYTE CORP For: Sep 30 Filed by: BAKER FELIX October 2, 2019 5:16 PM - SEC Filing Form 4 INCYTE CORP For: Sep 30 Filed by: FOUSE JACQUALYN A October 2, 2019 4:15 PM - SEC Filing Form 4 INCYTE CORP For: Sep 30 Filed by: DIXON WENDY L October 2, 2019 4:13 PM - SEC Filing Form 4 INCYTE CORP For: Sep 30 Filed by: Clancy Paul J October 2, 2019 4:09 PM - SEC Filing Form 4 INCYTE CORP For: Sep 30 Filed by: BROOKE PAUL A October 2, 2019 4:07 PM - SEC Filing Mizuho Securities Starts Incyte (INCY) at Buy October 2, 2019 4:04 PM - StreetInsider Form 4 INCYTE CORP For: Sep 30 Filed by: BIENAIME JEAN JACQUES October 2, 2019 4:04 PM - SEC Filing Incyte (INCY) PT Raised to $110 at JMP Securities September 30, 2019 4:36 AM - StreetInsider Cowen Reiterates Outperform Rating on Incyte (INCY); Possible Best in Class Status September 27, 2019 1:34 PM - StreetInsider Incyte (INCY) PT Raised to $101 at Guggenheim September 27, 2019 1:32 PM - StreetInsider Incyte (INCY) Reports Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients September 27, 2019 8:01 AM - StreetInsider Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma September 27, 2019 8:00 AM - BizWire Incyte (INCY) Reports First Patient Treatment in Ph. 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo September 25, 2019 7:31 AM - StreetInsider Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo September 25, 2019 7:30 AM - BizWire BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals September 25, 2019 6:30 AM - Globe NewsWire Incyte to Host Investor Conference Call from ESMO 2019 September 23, 2019 7:30 AM - BizWire Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J September 19, 2019 4:35 PM - SEC Filing Form 4 INCYTE CORP For: Sep 17 Filed by: Flannelly Barry P September 19, 2019 4:31 PM - SEC Filing BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia September 16, 2019 6:30 AM - Globe NewsWire UPDATE: BMO Capital Starts Incyte (INCY) at Market Perform September 11, 2019 4:33 PM - StreetInsider Form 4 INCYTE CORP For: Sep 09 Filed by: Pasquale Maria E September 11, 2019 4:30 PM - SEC Filing BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49 September 9, 2019 5:33 PM - Globe NewsWire Incyte (INCY) PT Raised to $87 at Morgan Stanley September 5, 2019 7:54 AM - StreetInsider JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform September 5, 2019 3:40 AM - StreetInsider Morgan Stanley Assumes Incyte (INCY) at Equalweight September 5, 2019 3:37 AM - StreetInsider Oppenheimer Upgrades Incyte (INCY) to Outperform September 5, 2019 3:28 AM - StreetInsider Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month September 3, 2019 9:00 AM - BizWire Incyte (INCY) Announces Data from its Oncology Portfolio to be Featured at ESMO September 3, 2019 8:14 AM - StreetInsider Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress September 3, 2019 8:14 AM - BizWire Companies with NDRs 09/03 September 3, 2019 6:47 AM - StreetInsider BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 August 27, 2019 6:30 AM - Globe NewsWire Eli Lilly & Co. (LLY), Incyte (INCY) Baricitinib Met Primary Endpoint in BREEZE-AD7 Trial August 23, 2019 2:58 PM - StreetInsider Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis August 23, 2019 2:56 PM - PR NewsWire Incyte to Present at Upcoming Investor Conferences August 22, 2019 8:00 AM - BizWire Incyte (INCY) granted FDA Orphan Drug Status for Pemigantinib August 21, 2019 4:02 PM - StreetInsider Form 4 INCYTE CORP For: Aug 15 Filed by: SWAIN PAULA J August 19, 2019 4:22 PM - SEC Filing Full Article List